Intellia Therapeutics (NTLA) Net Income (2015 - 2026)
Intellia Therapeutics (NTLA) posted quarterly Net Income of -$192.2 million for Q1 2026, up 24.62% year-over-year from -$154.2 million in Q1 2025, and down 108.23% quarter-over-quarter from -$92.3 million in Q4 2025.
Intellia Therapeutics (NTLA) Net Income (2015 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has reported Net Income for 12 consecutive years, with -$192.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income rose 24.62% year-over-year to -$192.2 million; the TTM figure through Mar 2026 stood at -$625.1 million (up 6.34% YoY), while the FY2025 annual figure was -$1.3 billion, down 4.47% from the prior year.
- Net Income eased to -$192.2 million in Q1 2026 per NTLA's latest filing, from -$92.3 million in the prior quarter.
- Across five years, Net Income topped out at -$92.3 million in Q4 2025 and bottomed at -$559.5 million in Q4 2022.
- Historically, Net Income has averaged -$201.4 million across 5 years, with a median of -$163.4 million in 2023.
- Annual changes were most pronounced in 2022 — Net Income surged 80.49% — and 2025, when it tumbled 97.63%.
- Intellia Therapeutics' Net Income stood at -$559.5 million in 2022, then surged by 70.8% to -$163.4 million in 2023, then grew by 22.77% to -$126.2 million in 2024, then increased by 26.86% to -$92.3 million in 2025, then sank by 108.23% to -$192.2 million in 2026.
- Business Quant data shows NTLA's Net Income at -$192.2 million in Q1 2026, -$92.3 million in Q4 2025, and -$222.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Intellia Therapeutics | 1.67 Bn | 1.67 Bn | - | -193.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -193.79 Mn |
| Mar 31, 2026 | -192.17 Mn |
| Dec 31, 2025 | -92.28 Mn |
| Sep 30, 2025 | -222.41 Mn |
| Jun 30, 2025 | -118.23 Mn |
| Mar 31, 2025 | -254.93 Mn |
| Dec 31, 2024 | -126.17 Mn |
| Sep 30, 2024 | -143.90 Mn |
| Jun 30, 2024 | -142.44 Mn |
| Mar 31, 2024 | -128.99 Mn |
| Dec 31, 2023 | -163.36 Mn |
| Sep 30, 2023 | -158.19 Mn |
| Jun 30, 2023 | -188.32 Mn |
| Mar 31, 2023 | -159.36 Mn |
| Dec 31, 2022 | -559.53 Mn |
| Sep 30, 2022 | -220.59 Mn |
| Jun 30, 2022 | -203.53 Mn |
| Mar 31, 2022 | -348.58 Mn |
| Dec 31, 2021 | -384.69 Mn |
| Sep 30, 2021 | -673.57 Mn |